DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the rebranding of their acquired
ClinicalRM division into ICON Government and Public Health Solutions
(GPHS). ICON GPHS provide full service clinical development and staffing
services across multiple agencies in the US Government, Global
Non-Government Organizations (NGOs), Academic Institutions and others in
the global health space, and have extensive experience working with
multi-national public health organizations.
Following ICON's acquisition of ClinicalRM in 2016, the rebrand
demonstrates ICON's commitment to solving global health issues through
enhancing capabilities in vaccines and infectious diseases. With
extensive experience supporting over 200 clinical vaccine trials in over
40 countries worldwide, ICON is building a legacy in supporting global
public health, and is recognised as a qualified provider for the Bill
and Melinda Gates Foundation.
"The rebrand of ClinicalRM to ICON Government and Public Health
Solutions will both extend and solidify ICON's offering to government
services and all those in the global health arena," commented Dr. James
F. Cummings, President ICON Government and Public Health Solutions. "It
will also help ICON to further leverage our extensive network in Africa,
Asia and the Americas, to help solve some of the most pressing global
health challenges we face today."
ICON's Government and Public Health Solutions will continue to support
US Federal Research, the Public Health Sector including NGOs, to serve a
common mission of generating new and safe medical products for federal
and commercial clients worldwide. ICON GPHS provides expertise across
basic and applied research, infectious and neglected tropical diseases,
oncology, vaccines development and testing the response to biothreats.
ICON is widely recognised in the industry, with awards including ‘Best
in Class' CRO in vaccine research by the World Vaccine Congress in 2017
and 2014 and has been commended or shortlisted for this award
consistently over the past 6 years. ICON was also awarded Best Contract
Research Organisation in the 2017 Scrip Awards.
To learn more about ICON's Government and Public Health Solutions,
please visit: www.iconplc.com/GPHS
About ICON plc
ICON plc is a global provider of outsourced
drug development services to biopharma, medical device, government,
biosimilar and generic organisations. The company specialises in the
strategic development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently, operates
from 98 locations in 38 countries and has approximately 13,250 employees.
Further information is available at: www.iconplc.com/
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20180403005674/en/
For ICON
Weber Shandwick
Olivia Pimenta
+44
(0)207 067 0557
OPimenta@webershandwick.com
Source: ICON
News Provided by Acquire Media
